Novo Nordisk's (NVO.US) new weight-loss drug CagriSema is equally effective as Liraglutide (LLY.US), but with an unexpectedly high side effect rate of nearly 80%.

According to the China Finance APP, on June 22nd, Novo Nordisk (NVO.US) disclosed the complete data of two Phase III clinical trials of its new weight loss drug CagriSema, showing positive results in weight loss and improvement of metabolic indicators, but with a higher incidence of gastrointestinal side effects compared to the placebo group. This result is basically consistent with the interim data previously released, but did not fully meet the expectations of the capital market, leading to fluctuations in the company's stock price. It is worth noting that the company experienced a change in personnel last month, with CEO Lars Fruergaard Jorgensen being dismissed.